Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 8Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasm Metastasis 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer 1Colorectal Neoplasms 1Castrate Sensitive Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Bulbo-Spinal Atrophy, X-Linked 1Bites and Stings 1

Interventions

Nivolumab 21cabozantinib 12Specimen Handling 11Ipilimumab 10belzutifan 9pembrolizumab 8Magnetic Resonance Spectroscopy 8CTLA-4 Antigen 5Biopsy 5Axitinib 5lenvatinib 4Sunitinib 4Immunoglobulin G 3Disulfides 3zimberelimab 2tivozanib 2relatlimab 2pazopanib 2palbociclib 2atezolizumab 2aldesleukin 2X-Rays 2Watchful Waiting 2Radiosurgery 2Nephrectomy 2Bevacizumab 2ulixertinib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × abiraterone × 30 days × Clear all
NCT07620574 2026-06-02

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Exelixis

Phase 3 Not yet recruiting
5,000 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡